🔗 Share this article

This year's Nobel Prize in medical science was granted for transformative findings that clarify how the body's defense network targets harmful infections while sparing the healthy tissues.

Three renowned researchers—Japan's Prof. Sakaguchi and US scientists Mary Brunkow and Dr. Ramsdell—share this accolade.

The work uncovered unique "security guards" within the defense system that remove rogue defense cells that could attacking the organism.

These findings are now paving the way for innovative therapies for immune disorders and malignancies.

These winners will share a prize fund worth 11m SEK.

Crucial Findings

"The research has been decisive for comprehending how the body's defenses functions and the reason we do not all suffer from serious autoimmune diseases," stated the chair of the Nobel Committee.

This team's studies address a core question: In what way does the defense system defend us from countless infections while keeping our healthy cells intact?

Our immune system employs white blood cells that scan for indicators of disease, even viruses and bacteria it has not met before.

Such cells utilize detectors—called receptors—that are generated randomly in a vast number of variations.

That provides the immune system the ability to fight a broad range of invaders, but the unpredictability of the process inevitably produces white blood cells that may attack the body.

Protectors of the Immune System

Researchers earlier knew that some of these harmful defense cells were destroyed in the immune organ—the site where white blood cells mature.

This year's Nobel Prize recognizes the identification of T-reg cells—described as the body's "security guards"—which patrol the body to neutralize other defenders that assault the healthy cells.

We know that this process malfunctions in self-attack conditions such as type-1 diabetes, MS, and rheumatoid arthritis.

The Nobel panel added, "These findings have laid the foundation for a new field of investigation and spurred the development of innovative therapies, for instance for cancer and autoimmune diseases."

Regarding cancer, regulatory T-cells prevent the system from attacking the tumor, so research are focused on lowering their numbers.

For autoimmune diseases, experiments are testing boosting regulatory T-cells so the body is not being harmed. A comparable method could also be effective in reducing the chances of transplanted organ failure.

Innovative Experiments

Prof Shimon Sakaguchi, of Osaka University, performed tests on rodents that had their thymus extracted, leading to autoimmune disease.

He showed that introducing immune cells from other animals could stop the disease—suggesting there was a mechanism for preventing defenders from attacking the body.

Dr. Brunkow, from the a research center in Seattle, and Dr. Ramsdell, now at a biotech firm in a California city, were investigating an inherited autoimmune disease in rodents and humans that led to the identification of a genetic factor critical for how regulatory T-cells operate.

"The groundbreaking research has revealed how the immune system is kept in check by regulatory T cells, preventing it from accidentally targeting the healthy cells," said a prominent biological science expert.

"The work is a remarkable illustration of how basic biological research can have broad consequences for human health."